Class Action Settlement Proposal Announced for Bayer ADR Holders in 2025

Proposed Class Action Settlement for Bayer ADR Holders

In a significant development within the legal landscape, Cohen Milstein Sellers & Toll PLLC has announced a proposed settlement of $38 million for individuals and entities who purchased Bayer American Depositary Receipts (ADRs) between May 23, 2016, and July 6, 2020. This class action settlement is poised to address alleged misconduct by the pharmaceutical giant and its leadership, which includes high-profile executives like Werner Baumann and Liam Condon.

Understanding the Settlement

The United States District Court for the Northern District of California, under the jurisdiction of Judge Richard Seeborg, will hold a hearing on October 30, 2025, to evaluate the fairness and reasonableness of the proposed settlement. During this hearing, several crucial aspects will be addressed:
1. Whether the proposed class action settlement should be approved.
2. Whether the action should be dismissed with prejudice against Bayer and its executives.
3. Evaluation of the plan of allocation for settlement funds.
4. Consideration of the attorneys' fees and litigation expenses requested by the lead counsel.

Who is Affected?

Current and former holders of Bayer ADRs during the specified class period are classified as members of the affected class. It is critical that these individuals understand how their rights may be influenced by the ongoing proceedings. If you belong to this group and have not received the Notice and Proof of Claim and Release Form, you are encouraged to connect with the Claims Administrator to obtain the necessary documentation.

This notification is issued under Rule 23 of the Federal Rules of Civil Procedure, ensuring transparency and clarity regarding the class members' rights and responsibilities.

Settlement Details

The $38 million settlement aims to compensate individuals who suffered losses as a result of alleged misconduct by Bayer. To receive a payout, class members must submit their Claim Form, postmarked no later than October 16, 2025. Failure to submit a proper Claim Form will result in the forfeiture of entitlement to participate in the settlement.

Opting Back Into the Class

For individuals who previously requested to opt-out from the class, there is an option to opt back into the class to regain eligibility for the settlement payout. Such requests must be submitted in writing by October 9, 2025. Those who do not opt back in will not be bound by the court's judgments or decisions related to the settlement.

Filing Objections

Class members retain the right to contest the proposed settlement, the allocation plan, or the attorneys' fees. Any objections must be submitted to the court and delivered to both the lead counsel and defense counsel by no later than October 9, 2025.

How to Get Additional Information

For additional inquiries, class members may contact the Claims Administrator or lead counsel. Engagement should not be directed toward the court or the defendant's attorneys, as they cannot provide information regarding the settlement notice. Details for reaching out are provided in the Notice and the relevant web links.

Conclusion

As this class action progresses, it reflects the ongoing scrutiny companies face regarding their fiduciary responsibilities. Anyone impacted by the proposed Bayer class action settlement should stay informed and understand the implications their participation may have on their rights and possible financial recovery.